goeasy Ltd. (GSY) Analysts See $0.81 EPS; Theravance Biopharma (TBPH) Sentiment Is 1.32

February 15, 2018 - By Peter Erickson

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.59 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

Analysts expect goeasy Ltd. (TSE:GSY) to report $0.81 EPS on February, 21.They anticipate $0.21 EPS change or 35.00% from last quarter’s $0.6 EPS. T_GSY’s profit would be $10.92M giving it 11.01 P/E if the $0.81 EPS is correct. After having $0.81 EPS previously, goeasy Ltd.’s analysts see 0.00% EPS growth. The stock increased 1.19% or $0.42 during the last trading session, reaching $35.67. About 30,940 shares traded or 32.86% up from the average. goeasy Ltd. (TSE:GSY) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on February, 26. They expect $-1.15 EPS, up 15.44% or $0.21 from last year’s $-1.36 per share. After $-1.27 actual EPS reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts -9.45% EPS growth.

Since January 1, 0001, it had 0 buys, and 1 sale for $451,350 activity.

Cormorant Asset Management Llc holds 5.74% of its portfolio in Theravance Biopharma, Inc. for 950,000 shares. Foundation Asset Management Lp owns 432,532 shares or 4.61% of their US portfolio. Moreover, Baupost Group Llc Ma has 3.97% invested in the company for 9.31 million shares. The Massachusetts-based Opaleye Management Inc. has invested 2.18% in the stock. Old West Investment Management Llc, a California-based fund reported 113,942 shares.

Ratings analysis reveals 50% of Theravance Biopharma’s analysts are positive. Out of 2 Wall Street analysts rating Theravance Biopharma, 1 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. The lowest target is $24.0 while the high is $40.0. The stock’s average target of $32 is 8.92% above today’s ($29.38) share price. TBPH was included in 2 notes of analysts from October 12, 2016. The firm earned “Underperform” rating on Wednesday, October 12 by Robert W. Baird. Needham initiated the stock with “Buy” rating in Wednesday, December 21 report.

The stock increased 4.41% or $1.24 during the last trading session, reaching $29.38. About 127,171 shares traded. Theravance Biopharma, Inc. (TBPH) has risen 89.85% since February 15, 2017 and is uptrending. It has outperformed by 73.15% the S&P500.

goeasy Ltd. provides goods and alternative financial services that enhance the lives of everyday Canadians. The company has market cap of $480.70 million. It operates through two divisions, easyfinancial and easyhome. It has a 12.84 P/E ratio. The easyfinancial segment provides short-term unsecured consumer loans and related financial services, such as loan protection plans, home and auto benefit plans, and credit monitoring services.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>